Selective activation of oxygen-deprived tumor-infi ltrating lymphocytes through local intratumoral delivery of CD137 monoclonal antibodies

Cancer Discovery

Volumn 2, Issue 7, 2012, Pages 586-587

  Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMMUNOSTIMULATING AGENT; INTERLEUKIN 15; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; OXYGEN; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; DENDRITIC CELL; DISTANT METASTASIS; DRUG MEGADOSE; HUMAN; HYPOXIA; LIVER TOXICITY; LOW DRUG DOSE; LYMPH NODE; SPLENOMEGALY; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALS; ANOXIA; ANTIGENS, CD137; FEMALE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; NEOPLASMS; T-LYMPHOCYTES;

EID: 84866325703     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0229     Document Type: Article

References (10)

1. Palazón A, Martínez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, de Sanmamed MF, et al. The HIF-1AAhypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov 2012;2:608-23.
2. Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012;11:1062-70.
3. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010;37:508-16.
4. Shao Z, Schwarz H. CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction. J Leukoc Biol 2011;89:21-9.
5. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012;12:9-22.
6. Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 2011;17:2270-80.
7. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase IrII study. J Clin Oncol 2010;28:4324-32.
8. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, et al. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1i2 study. Blood 2012;119:355-63.
9. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011;117:2423-32.
10. Ly LV, Sluijter M, Versluis M, Luyten GP, van Stipdonk MJ, van der Burg SH, et al. Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res 2010;70:8339-46.